TABLE 2.

Proposed target levels of anti-tumor necrosis factors (anti-TNFs) for clinical decision making based on published data and expert opinion.

Clinical time point	Infliximab	Adalimumab	Golimumab
After induction (week 14)	4–15 μg/mL (163)	N/D	N/D
During remission (therapeutic)	4–8 μg/mL (164–167)	5–10 μg/mL (163, 165–167)	1.4–4 μg/mL* (168–171)
To treat flare or before discontinuing due to loss of response (supratherapeutic)	>10 μg/mL (163)	>12 μg/mL (163)	N/D
For fistula healing	>12 μg/mL (172)	>14 μg/mL	N/A

N/A, not applicable; N/D, no consistent data; TDM, therapeutic dose monitoring; *Assay dependent.